COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.



San Diego Center for Precision Immunotherapy

Speaker Series 2021



"Engineering Cancer Immunity"

Hosted by Nisarg Shah, Ph.D., University of California, San Diego, Assistant Professor, Department of Nanoengineering, Chemical Engineering Program

Session 2​

Wednesday, February 24, 2021  1PM (PST)  Recording coming soon.

“Targeting the Lymph Nodes to Induce Potent Immunity in Oncology and Infectious Disease”

"Bioengineering approaches to infectious disease (SARS-CoV-2)" 


Peter DeMuth, PhD

Founding Scientist and Vice President of Research, Elicio Therapeutics

Dr. Pete DeMuth is a founding scientist at Elicio and currently serves as vice president of research, leading the development of technology platforms for infectious disease vaccines and cancer immunotherapeutics from early research to clinical development. To this role, he brings over 10 years of experience in oncology, immunology and materials science.
Prior to joining Elicio, Pete oversaw efforts to develop novel technologies for vaccination and immunotherapy at the Massachusetts Institute of Technology’s Koch Institute for Integrative Cancer Research in affiliation with the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University, where he received recognition from the National Institutes of Health and the American Chemical Society.
In 2015, Pete received the Quadrant Award from Quadrant AG, a global manufacturer and innovator in polymer materials science, for research he completed while at the Koch Institute at MIT.
Pete has also been an NIH Fellow at the Whitehead Institute for Biomedical Research and a research fellow at Novartis Vaccines and Diagnostics. As a Howard Hughes Research Fellow at the University of Maryland, he was awarded the University Medal for his development of advanced technologies for oncology therapeutics.


Session 1

Wednesday, February 10, 2021  1PM (PST) Recording Coming Soon.

“Engineering more effective cancer immunotherapies via drug delivery technologies”

Darrell Irvine, Ph.D.

Professor, Departments of Biological Engineering and Materials Science & Engineering
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Ragon Institute of MGH, MIT, and Harvard
Investigator, Howard Hughes Medical Institute

Dr. Irvine obtained an Honors Bachelor’s degree in Engineering Physics from the University of Pittsburgh. As a National Science Foundation graduate fellow he then studied Polymer Science at the Massachusetts Institute of Technology. Following completion of his Ph.D., he was a Damon Runyon-Walter Winchell postdoctoral fellow in immunology at the Beckman Center for Molecular and Genetic Medicine. He is presently a Professor at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. He is also an Associate Director for the Koch Institute for Integrative Cancer Research at MIT and serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard.


April Speaker Series

Hosted by Susan Kaech, Ph.D.,  Professor and Director of the NOMIS Center for Immunobiology and Microbial Pathogenesis, Salk institute for Biological Studies

Wednesday, April 28, 2021 at 1PM (PST)

"Understanding Acquired Resistance to Immunotherapy in Lung Cancer”


Katerina Politi, Ph.D.

Cancer Signaling Networks;
Experimental Pathology Graduate Program;  K12 Calabresi Immuno-Oncology Training Program (IOTP);
Molecular Cell Biology, Genetics and Development;  Molecular Medicine, Pharmacology, and Physiology
Office of Cooperative Research
Pathology; Pathology Research
Politi Lab SPORE in Lung Cancer
Yale Cancer Center;
Yale Center for Immuno-Oncology;
Yale Combined Program in the Biological and Biomedical Sciences (BBS); Yale Stem Cell Center

Katerina Politi studied Biology at the University of Pavia in Italy. She then moved to New York, where she obtained her PhD in Genetics and Development working with Argiris Efstratiadis at Columbia University. Following graduate school, she joined Harold Varmus's lab at Memorial Sloan-Kettering Cancer Center and began her work on the molecular basis of lung cancer. She continues this work at Yale as an Associate Professor in the Departments of Pathology and Internal Medicine (in the Section of Medical Oncology). Her laboratory is focused on studying the biology of lung cancer and on uncovering mechanisms of resistance to targeted therapies and immunotherapies in this disease. At the Yale Cancer Center, Dr. Politi is a co-leader of the Cancer Signaling Networks Research Program.